An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1465-542X
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer ; volume:23 ; number:1 ; day:4 ; month:3 ; year:2021 ; pages:1-12 ; date:12.2021
Breast cancer research ; 23, Heft 1 (4.3.2021), 1-12, 12.2021

Creator
Stringer-Reasor, Erica M.
May, Jori E.
Olariu, Eva
Caterinicchia, Valerie
Li, Yufeng
Chen, Dongquan
Della Manna, Deborah L.
Rocque, Gabrielle B.
Vaklavas, Christos
Falkson, Carla I.
Nabell, Lisle M.
Acosta, Edward P.
Forero-Torres, Andres
Yang, Eddy S.
Contributor
SpringerLink (Online service)

DOI
10.1186/s13058-021-01408-9
URN
urn:nbn:de:101:1-2021041814365191621257
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:46 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Stringer-Reasor, Erica M.
  • May, Jori E.
  • Olariu, Eva
  • Caterinicchia, Valerie
  • Li, Yufeng
  • Chen, Dongquan
  • Della Manna, Deborah L.
  • Rocque, Gabrielle B.
  • Vaklavas, Christos
  • Falkson, Carla I.
  • Nabell, Lisle M.
  • Acosta, Edward P.
  • Forero-Torres, Andres
  • Yang, Eddy S.
  • SpringerLink (Online service)

Other Objects (12)

Metastatic Triple-Negative Breast Cancer

Metastatic Triple-Negative Breast Cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

Metastatic and triple-negative breast cancer: challenges and treatment options

Practical consensus recommendations on management of triple-negative metastatic breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer

CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients

A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients

Related objects